Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major ...

Myeloperoxidase (MPO)-derived oxidants reduce nitric oxide bioavailability and promote coronary microvascular dysfunction, cardiomyocyte stiffening and interstitial fibrosis—mechanisms implicated in ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

Hyperuricemia may causally contribute to PAH, positioning uric acid as a potential therapeutic target for treatment and prevention. Mendelian randomization analysis suggests a genetic-level causal ...

A new phase 3 study comparing mono and duo therapies may yield greater guidance and treatment options for children with pulmonary arterial hypertension (PAH). PAH is a rare condition in children, but ...